Mizuho Begins Coverage on Castle Biosciences (NASDAQ:CSTL)

Posted by Geri Gentry on Oct 29th, 2026

Research analysts at Mizuho initiated coverage on shares of Castle Biosciences (NASDAQ:CSTL – Get Free Report) in a research report issued on Thursday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $60.00 price target on the stock. Mizuho‘s price objective would suggest a potential upside of 63.58% from the stock’s previous close.

Several other brokerages also recently weighed in on CSTL. Wall Street Zen downgraded Castle Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 24th. BTIG Research raised their target price on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Weiss Ratings raised Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. Finally, Robert W. Baird set a $36.00 price target on Castle Biosciences in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $44.25.

Get Our Latest Report on CSTL

Castle Biosciences Stock Up 6.3%

Shares of Castle Biosciences stock opened at $36.68 on Thursday. Castle Biosciences has a twelve month low of $17.72 and a twelve month high of $44.28. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -55.58 and a beta of 0.94. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. The company has a fifty day moving average price of $34.01 and a 200 day moving average price of $28.69.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.34. The company had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. Equities research analysts forecast that Castle Biosciences will post -1.29 earnings per share for the current fiscal year.

Insider Activity at Castle Biosciences

In other Castle Biosciences news, insider Tobin W. Juvenal sold 3,288 shares of the business’s stock in a transaction on Monday, October 26th. The shares were sold at an average price of $33.08, for a total value of $108,767.04. Following the transaction, the insider owned 45,431 shares in the company, valued at $1,502,857.48. The trade was a 6.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen M. Oelschlager sold 4,153 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $35.95, for a total transaction of $149,300.35. Following the completion of the transaction, the chief operating officer directly owned 13,356 shares of the company’s stock, valued at approximately $480,148.20. The trade was a 23.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 214,894 shares of company stock valued at $6,976,395. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Castle Biosciences

Several large investors have recently modified their holdings of CSTL. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Castle Biosciences in the third quarter worth $55,000. China Universal Asset Management Co. Ltd. boosted its stake in Castle Biosciences by 15.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,574 shares of the company’s stock valued at $194,000 after acquiring an additional 747 shares during the last quarter. NFSG Corp bought a new position in Castle Biosciences during the 3rd quarter valued at $36,000. Green Alpha Advisors LLC grew its holdings in Castle Biosciences by 39.1% during the 3rd quarter. Green Alpha Advisors LLC now owns 13,828 shares of the company’s stock worth $491,000 after acquiring an additional 3,887 shares in the last quarter. Finally, Tidal Investments LLC acquired a new position in Castle Biosciences during the 2nd quarter worth $529,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Castle Biosciences

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.